Clinical Trial Update: CYTALUX™for the Intraoperative Imaging of Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting the completion of a study evaluating CYTALUX as an intraoperative imaging agent for prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Cytalux (pafolacianine)

Snippet

Sponsor: Indiana University | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED